321 related articles for article (PubMed ID: 25953704)
1. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.
Oden F; Marino SF; Brand J; Scheu S; Kriegel C; Olal D; Takvorian A; Westermann J; Yilmaz B; Hinz M; Daumke O; Höpken UE; Müller G; Lipp M
Mol Oncol; 2015 Aug; 9(7):1348-58. PubMed ID: 25953704
[TBL] [Abstract][Full Text] [Related]
2. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
3. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
4. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
[TBL] [Abstract][Full Text] [Related]
5. Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models.
Shancer Z; Liu XF; Nagata S; Zhou Q; Bera TK; Pastan I
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4592-4598. PubMed ID: 30782819
[TBL] [Abstract][Full Text] [Related]
6. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
7. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
8. B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma.
Eckhert E; Hewitt R; Liedtke M
Immunotherapy; 2019 Jun; 11(9):801-811. PubMed ID: 31094254
[TBL] [Abstract][Full Text] [Related]
9. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
Sanchez E; Gillespie A; Tang G; Ferros M; Harutyunyan NM; Vardanyan S; Gottlieb J; Li M; Wang CS; Chen H; Berenson JR
Clin Cancer Res; 2016 Jul; 22(13):3383-97. PubMed ID: 26960399
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
Lin L; Cho SF; Xing L; Wen K; Li Y; Yu T; Hsieh PA; Chen H; Kurtoglu M; Zhang Y; Andrew Stewart C; Munshi N; Anderson KC; Tai YT
Leukemia; 2021 Mar; 35(3):752-763. PubMed ID: 32632095
[TBL] [Abstract][Full Text] [Related]
12. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
[TBL] [Abstract][Full Text] [Related]
13. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
Chen H; Li M; Xu N; Ng N; Sanchez E; Soof CM; Patil S; Udd K; Bujarski S; Cao J; Hekmati T; Ghermezi M; Zhou M; Wang EY; Tanenbaum EJ; Zahab B; Schlossberg R; Yashar MA; Wang CS; Tang GY; Spektor TM; Berenson JR
Leuk Res; 2019 Jun; 81():62-66. PubMed ID: 31035033
[TBL] [Abstract][Full Text] [Related]
14. Cellular membrane-based vesicles displaying a reconstructed B cell maturation antigen for multiple myeloma therapy by dual targeting APRIL and BAFF.
He C; Zhang M; Liu L; Han Y; Xu Z; Xiong Y; Yan F; Su D; Chen H; Zheng Y; Cheng F
Acta Biomater; 2022 Apr; 143():406-417. PubMed ID: 35218967
[TBL] [Abstract][Full Text] [Related]
15. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
16. Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation.
Bera TK
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33003418
[TBL] [Abstract][Full Text] [Related]
17. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
Tai YT; Anderson KC
Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
[No Abstract] [Full Text] [Related]
18. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma.
Bilich T; Nelde A; Bauer J; Walz S; Roerden M; Salih HR; Weisel K; Besemer B; Marcu A; Lübke M; Schuhmacher J; Neidert MC; Rammensee HG; Stevanović S; Walz JS
Blood Cancer J; 2020 Feb; 10(2):24. PubMed ID: 32111817
[TBL] [Abstract][Full Text] [Related]
19. B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives.
Sellner L; Fan F; Giesen N; Schubert ML; Goldschmidt H; Müller-Tidow C; Dreger P; Raab MS; Schmitt M
Int J Cancer; 2020 Oct; 147(8):2029-2041. PubMed ID: 32270481
[TBL] [Abstract][Full Text] [Related]
20. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
Tai YT; Mayes PA; Acharya C; Zhong MY; Cea M; Cagnetta A; Craigen J; Yates J; Gliddon L; Fieles W; Hoang B; Tunstead J; Christie AL; Kung AL; Richardson P; Munshi NC; Anderson KC
Blood; 2014 May; 123(20):3128-38. PubMed ID: 24569262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
